Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response
US9095537B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 16, 2007 |
| Grant date | Aug 4, 2015 |
| Priority date | — |
| Expiry date | Feb 11, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y406/01001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises:(i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds;(ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally;(iii) an adjuvant component suitable for activating the innate immune response in a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.